Literature DB >> 20076865

Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma.

Leandro Totti Cavazzola1, André Ricardo Pereira da Rosa, Carlos Cauduro Schirmer, Richard Ricachenevski Gurski, João Pedro Bueno Telles, Fernando Mielke, Luíse Meurer, Maria Isabel Albano Edelweiss, Cleber Dario Pinto Kruel.   

Abstract

OBJECTIVES: To correlate the expression of p53 protein and VEGF with the prognosis of patients submitted to curative resection to treat esophageal adenocarcinoma.
METHODS: Forty-six patients with esophageal adenocarcinoma, submitted to curative resection, were studied. The expressions of p53 protein and VEGF were assessed by immunohistochemistry in 52.2% and 47.8% of tumors, respectively.
RESULTS: P53 protein and VEGF expressions coincided in 26% of the cases, and no correlation between these expressions was observed. None of the clinicopathological factors showed a significant correlation with p53 protein or VEGF expressions. There was no significant association between p53 protein and VEGF expressions and long-term survival.
CONCLUSION: The expression of p53 protein and VEGF did not correlate with prognosis in esophageal adenocarcinoma patients submitted to curative resection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20076865     DOI: 10.1590/s0100-69912009000100007

Source DB:  PubMed          Journal:  Rev Col Bras Cir        ISSN: 0100-6991


  9 in total

1.  The expression and significance of vascular endothelial growth factor A in adenoid cystic carcinoma of palatal salivary gland.

Authors:  Haitao Liu; Linlin Chen; Chenliang Wang; Haibo Zhou
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-04       Impact factor: 2.503

Review 2.  Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Authors:  L H McCormick Matthews; F Noble; J Tod; E Jaynes; S Harris; J N Primrose; C Ottensmeier; G J Thomas; T J Underwood
Journal:  Br J Cancer       Date:  2015-06-25       Impact factor: 7.640

Review 3.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

4.  Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.

Authors:  C-I Geppert; P Rümmele; M Sarbia; R Langer; M Feith; L Morrison; E Pestova; R Schneider-Stock; A Hartmann; T T Rau
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

5.  Pattern of p53 protein expression is predictive for survival in chemoradiotherapy-naive esophageal adenocarcinoma.

Authors:  Fiebo J C Ten Kate; Lucia Suzuki; Lambert C J Dorssers; Winand N M Dinjens; David T W Jones; Daan Nieboer; Michael Doukas; J Jan B Van Lanschot; Bas P L Wijnhoven; Leendert H J Looijenga; Katharina Biermann
Journal:  Oncotarget       Date:  2017-10-24

6.  Evaluation of Cyclooxygenase-2 and p53 Expression in Pterygium Tissue Following Preoperative Intralesional Ranibizumab Injection.

Authors:  Ahmad Razif Omar; Mohtar Ibrahim; Hasnan Jaafar; Ab Hamid Siti-Azrin; Embong Zunaina
Journal:  Front Med (Lausanne)       Date:  2021-12-24

7.  Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells.

Authors:  Jianwu Hu; Caiyun Chen; Yuan Su; Jiao DU; Xin Qian; Yang Jin
Journal:  Exp Ther Med       Date:  2012-09-10       Impact factor: 2.447

8.  Prognostic significance of p53 expression in patients with esophageal cancer: a meta-analysis.

Authors:  Lianghai Wang; Xiaodan Yu; Jing Li; Zhiyu Zhang; Jun Hou; Feng Li
Journal:  BMC Cancer       Date:  2016-07-01       Impact factor: 4.430

Review 9.  The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Oliver M Fisher; Sarah J Lord; Dan Falkenback; Nicholas J Clemons; Guy D Eslick; Reginald V Lord
Journal:  Gut       Date:  2016-01-05       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.